Alkermes completes patient enrollment in Phase II ALKS 3831 trial to treat schizophrenia
ALKS 3831 is composed of samidorphan, a new, potent mu-opioid antagonist, in combination with an antipsychotic drug, olanzapine. The trial is designed to evaluate the efficacy, safety and